Gene Variants Related to Cardiovascular and Pulmonary Diseases May Correlate with Severe Outcome of COVID-19

Int J Mol Sci. 2022 Aug 4;23(15):8696. doi: 10.3390/ijms23158696.

Abstract

Background: Severe outcomes of COVID-19 account for up to 15% of all cases. The study aims to check if any gene variants related to cardiovascular (CVD) and pulmonary diseases (PD) are correlated with a severe outcome of COVID-19 in a Polish cohort of COVID-19 patients. Methods: In this study, a subset of 747 samples from unrelated individuals collected across Poland in 2020 and 2021 was used and whole-genome sequencing was performed. Results: The GWAS analysis of SNPs and short indels located in genes related to CVD identified one variant significant in COVID-19 severe outcome in the HADHA gene, while for the PD gene panel, we found two significant variants in the DRC1 gene. In this study, both potentially protective and risk variants were identified, of which variants in the HADHA gene deserve the most attention. Conclusions: This is the first study reporting the association between the HADHA and DRC1 genetic variants and COVID-19 severe outcome based on the cohort WGS analysis. Although all the identified variants are localised in introns, they may be correlated and therefore inherited along with other risk variants, potentially causative to severe outcome of COVID-19 but not discovered yet.

Keywords: COVID-19; GWAS; cardiovascular diseases; genetic variants; pulmonary diseases; risk factors; single nucleotide polymorphism.

MeSH terms

  • COVID-19* / genetics
  • Cardiovascular Diseases* / genetics
  • Genome-Wide Association Study
  • Humans
  • INDEL Mutation
  • Lung
  • Polymorphism, Single Nucleotide

Grants and funding

This research was partially funded by the National Centre for Research and Development project “Szpitale Jednoimienne/02/2020”, “Development of an innovative diagnostic test to assess the course of COVID-19 and post-death complications with the aid of whole-genome analysis”, as well as the Medical Research Agency project 2020/ABM/COVID19/0022 “A clinical trial in the search for genetic markers responsible for the intensity of the course of the COVID-19 disease, with particular emphasis on patients with accompanying cardiopulmonary diseases”.